Cell therapy company Talaris Therapeutics raises $100m in Series A round
Talaris Therapeutics (formerly Regenerex) has raised $100 million in a Series A financing round to advance its allogeneic cell therapy FCR001 into phase 3 development in various immune-related indications. Blackstone Life Sciences led the financing round of the US biotech company with the other participants being Qiming Venture Partners USA and Longitude Capital. Talaris Therapeutics […]